Navigation Links
Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
Date:10/14/2008

BOSTON, Oct. 14 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (OTC Pink Sheets: SNDY) is pleased to announce that the Company is in the final stages to upgrade its status on the Pinksheets Electronic OTC Markets from Limited Information to Current Information. The Company is in the process of completing their Issuer Information Statement, which will be accompanied by an attorney's opinion letter. The Company expects to have its status upgraded by the end of the quarter.

A Pinksheets status of current information indicates that Solos Endoscopy, Inc. will make its current information publicly available through the OTC Disclosure and News Service according to the Pink OTC Markets manual: Guidelines for Providing Adequate Current Information. There are currently 1,111 companies trading under current information as opposed to 521 companies trading under limited information. The 1,111 companies trading under current information represented approximately 65.4% of the total dollar volume traded during the month of December 2007, according to Pinksheets.com.

"By upgrading our status to current information, we are demonstrating to our shareholders that we are working hard to increase the value of our stock as we move forward with our business strategy over the next several months," stated Bob Segersten, President of Solos Endoscopy, Inc.

Please click on the link to view the Guidelines for Providing Adequate Current Information. (http://www.pinksheets.com/content/doc/ps/Disclosure/Guidelines/2.pdf)

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: http://www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
2. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
3. Essilor Finalizes Satisloh Agreement
4. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
5. 2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced
6. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. Prix Galien USA Announces 2008 Final Candidates
9. White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product
10. Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
11. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers ... research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, and ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of the latest paper by its Science Editor, Dr. Elisabeth Bik, in the ... Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from her previous position ...
(Date:1/18/2017)... 2017 Shareholder rights law firm Johnson & ... board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... the proposed sale of the Company to Eli Lilly ... small molecules for the acute treatment of migraines. ... signed a definitive merger agreement with Eli Lilly. Under ...
(Date:1/18/2017)... 2017  Caris Life Sciences, a leading innovator ... largest private funder of pancreatic cancer research, are ... impact of immunotherapy in the treatment of pancreatic ... to identify potential trial candidates based on biomarker ... and study investigators. The Lustgarten Foundation is a ...
Breaking Biology Technology:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):